According to a recent LinkedIn post from Cala Health, the company’s team participated in the 3rd International Tremor Congress in Tampa, engaging with movement disorder specialists and neurologists on developments in tremor research. The post highlights presentations on clinical evidence for wearable neuromodulation in Cala’s Transcutaneous Afferent Patterned Stimulation, or TAPS, therapy and on electrophysiologic and PET-based insights into treatment of refractory essential tremor.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The content suggests Cala Health is positioning its TAPS technology within the mainstream scientific and clinical community, which may support physician adoption and reimbursement discussions over time. For investors, active contribution to peer-reviewed discourse and evidence generation could strengthen the company’s competitive standing in noninvasive neuromodulation for movement disorders and potentially enhance the commercial prospects of its therapeutic platform if clinical data translate into broader clinical use.